BI 2536 Second Line Monotherapy in SCLC

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.

Phase 2

Boehringer Ingelheim